Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer

Gynecologic Oncology

Volumn 93, Issue 2, 2004, Pages 474-478

  Chiara, Silvana ^a   Tognoni, Alessandra ^b   Pastrone, Ilaria ^a   Tomasello, Laura ^a   Brema, Fulvio ^c   Di Costanzo, Gianna ^d   Folco, Ugo ^e   Pronzato, Paolo ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Dipartimento Interaziendale di Neuroscienze del Ponente Ligure   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e SANTA CORONA HOSPITAL   (Italy)

Author keywords

Ifosfamide; Ovarian cancer; Second line; Topotecan

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG DETERMINATION; FEVER; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MEDICAL ASSESSMENT; MEDICAL RECORD; NAUSEA; NEUTROPENIA; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IFOSFAMIDE; MIDDLE AGED; OVARIAN NEOPLASMS; SALVAGE THERAPY; TOPOTECAN;

EID: 1942508848     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.01.027     Document Type: Article

References (23)

1. McGuire W.P., Hoskins W.H., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y.et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
2. Piccard M.J., Bertelsen K., James K.et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 92:2000;699-708.
3. Blackledge G., Lawton F., Redman C., Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implication for patients treatment and the design of phase II trials. Br. J. Cancer. 59:1989;650-653.
4. Thigpen T., Vance R.B., McGuire W.P., Hoskins W.J., Brady M. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary. A review with emphasis on the Gynecologic Oncology Group experience. Semin. Oncol. 22:1995;23-31.
5. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B.et al. ICON4/AGO-OVAR-2.2 trial. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 361:2003;2099-2106.
6. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I.et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15:1997;2183-2193.
7. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19:2001;3312-3322.
8. Bookman M.A., Malmstrom H., Bolis G., Gordon A., Lissoni A., Krebs J.B.et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16:1998;3345-3352.
9. Markman M., Hakes T., Reichman B., Lewis J.L. Jr., Rubin S., Jones W.et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J. Clin. Oncol. 10:1992;243-248.
10. Smith M.J., Spencer S.A., Zhang R., Robert F. Phase I/II study of sequential ifosfamide and topotecan in patients with small cell lung cancer. Proc. ASCO. 17:1998;1927.
11. Rustin G.J., Nelstrop A.E., McClean P., Brady M.F., McGuire W.P., Hoskins W.J.et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125. J. Clin. Oncol. 14:1996;1545-1551.
12. Kudelka A.P., Tresukosol D., Edwards C.L., Freedman R.S., Levenback C., Chantarawiroj P.et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol. 14:1996;1552-1557.
13. Swisher E.M., Mutch D.G., Rader J.S., Elbendary A., Herzog T.J. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. 66:1997;480-486.
14. McGuire W.P., Blessing J.A., Bookman M.A., Lentz S.S., Dunton C.J. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 18:2000;1062-1067.
15. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol. Oncol. 79:2000;116-119.
16. Brown J.V. III, Peters W.A. III, Rettenmaier M.A., Graham C.L., Smith M.R., Drescher C.W.et al. Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol. Oncol. 88:2003;136-140.
17. Miller D.S., Blessing J.A., Lentz S.S., McMeekin D.S. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Cancer. 15:2003;1664-1669.
18. Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M.et al. Effects of CPT-11 in combination with other anticancer agents in culture. Int. J. Cancer. 50:1992;604-610.
19. Murren J.R., Anderson S., Fedele J., Pizzorno G., Belliveau D., Zelterman D.et al. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. J. Clin. Oncol. 15:1997;148-157.
20. Markman M., Kennedy A., Sutton G., Hurteau J., Webster K., Peterson G.et al. Phase II trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol. Oncol. 70:1998;272-274.
21. Schneider C.P., Merkel U., Grübner U., Kath R., Hoffken K., Hoffmann A. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solis tumors. J. Cancer Res. Clin. Oncol. 128:2002;313-318.
22. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S.et al. Second-line platinum-therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9:1991;389-393.
23. Kavanagh J., Tresukosol D., Edwards C., Freedman R., Gonzalez de Leon C., Fishman A.et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J. Clin. Oncol. 13:1995;1584-1588.